Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Conditions
Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary FrequencySummary
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
Detailed Description
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients who have a prior history of radical prostatectomy or radiation for prostate cancer or who have a history of cytoreductive surgical intervention for benign prostatic hyperplasia (BPH).
Locations
12 locations Found with status Recruiting
Status
- RECRUITING
Contact Person
- Alisha Hitt
Study Director
- Karen Noblett, MD
Status
- RECRUITING
Contact Person
- Pam Manley
Study Director
- Karen Noblett, MD
Status
- RECRUITING
Contact Person
- Annette West
Study Director
- Karen Noblett, MD
Status
- RECRUITING
Contact Person
- Vivian Cabral Perez
Study Director
- Karen Noblett, MD
Status
- RECRUITING
Contact Person
- Nicolle Acuna
Study Director
- Karen Noblett, MD
Status
- RECRUITING
Contact Person
- Jaya Mishra, PhD
Study Director
- Karen Noblett, MD
Status
- RECRUITING
Contact Person
- Sherry Stephens
Study Director
- Karen Noblett, MD
Status
- RECRUITING
Contact Person
- Angie Kostreba
Study Director
- Karen Noblett, MD
Status
- RECRUITING
Contact Person
- Lydia Beard
Study Director
- Karen Noblett, MD
Status
- RECRUITING
Contact Person
- Kason Ladd
Study Director
- Karen Noblett, MD
Status
- RECRUITING
Contact Person
- Melissa Howell
Study Director
- Karen Noblett, MD
Status
- RECRUITING
Contact Person
- Mariam Shittu
Study Director
- Karen Noblett, MD
Eligibility Criteria
Key Inclusion Criteria:
1. Participants aged ≥ 18 years at the time of enrollment
2. Able to complete bladder diaries and patient questionnaires
3. Primary diagnosis of OAB (urinary urgency incontinence (UUI) or urinary frequency (UF)).
4. Willing and capable to provide written informed consent and agrees to comply with specified evaluations at clinical investigational sites and attend all follow-up assessments for up to 1 year
Key Exclusion Criteria:
1. Any patient that is not a suitable candidate per investigator discretion
2. Recent prostate therapy or procedure within the last 6 months at the time of enrollment
3. Any neurological condition that could interfere with normal bladder function, including stroke, epilepsy, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or spinal cord injury (e.g., paraplegia)
4. Previously implanted with a sacral neuromodulation device, including inactive SNM devices
5. Any prior treatment with an Implantable Tibial Nerve Stimulation (ITNS)
6. Percutaneous Tibial Nerve Stimulation (PTNS) within the last 3 months at the time of enrollment
7. Underwent an external trial with any sacral neuromodulation device and was deemed a non-responder by a physician
8. Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study objectives at the Investigator's discretion.
9. Uncontrolled diabetes
10. Known allergic reactions to components of the Axonics SNM System, including titanium, zirconia, polyurethane, epoxy, or silicone
Study Plan
Post-prostatectomy
OTHER
History of radical prostatectomy for cancer treatment at least 6 months prior to enrollment
DEVICE:
Axonics SNM SystemDescription:
To assess clinical outcomes of the Axonics SNM System in the male OAB population.
Radiation
OTHER
History of radiation for cancer treatment at least 6 months prior to enrollment
DEVICE:
Axonics SNM SystemDescription:
To assess clinical outcomes of the Axonics SNM System in the male OAB population.
Benign Prostatic Hyperplasia (BPH)
OTHER
History of cytoreductive BPH surgery at least 6 months prior to enrollment
DEVICE:
Axonics SNM SystemDescription:
To assess clinical outcomes of the Axonics SNM System in the male OAB population.
Outcome Measures
Primary Outcome Measures
Adverse event reporting (Safety)
Performance/Effectiveness - Reduction in UUI or UF episodes
Secondary Outcome Measures
Performance/Effectiveness - Improvement in Quality of Life scoring
Timeline
Last Updated
August 11, 2025Start Date
July 19, 2024Today
October 19, 2025Completion Date ( Estimated )
December 1, 2027
Sponsors of this trial
Lead Sponsor
Axonics, Inc.